ER strikes again: Proteostasis Dysfunction In ALS.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.Brain : a journal of neurology · 2021
   Trial
2. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).BMJ open · 2017
   Trial
3. How Inflammation Pathways Contribute to Cell Death in Neuro-Muscular Disorders.Biomolecules · 2021
   Review
4. Motor Neuron Susceptibility in ALS/FTD.Frontiers in neuroscience · 2019
   Review
5. GRP78 at the Centre of the Stage in Cancer and Neuroprotection.Frontiers in neuroscience · 2017
   Review

Corrections and comments

• Comment on
  ALS-linked protein disulfide isomerase variants cause motor dysfunction.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as